Veradigm and the American College of Cardiology (ACC) are partnering to improve care and advance the next-generation of real-world research.
This network powers research for Life Science companies. In addition, the network will be leveraged by the ACC to inform guidelines and enhance programs.
For more information about Veradigm’s data, research and analytics capabilities for Life Science:
Veradigm and the ACC are working together to take the complexity of cardiovascular medicine and simplify it in ways that enable doctors to have the right information at the right time to make the best decisions for their patients.
Therapeutic inertia refers to the failure to advance therapy (or to de-intensify therapy) at the appropriate time. This phenomenon is caused by many factors, but it is known to contribute to poorer outcomes for patients due to delayed treatment, sometimes by many years*. The ACC and Veradigm are working to address this issue.
Patient Data can be analyzed to understand how care is being delivered and to identify areas of opportunity where treatment best practices aren’t being followed (geography, provider type, patient population, etc.). Based on this analysis, the ACC can then direct quality improvement programs, education programs and other interventions for targeted populations. Post implementation, additional data can be collected to understand program effectiveness and identify areas of further improvement.
*Clinical Diabetes 2019 Apr; 37(2): 105-106. https://doi.org/10.2337/cd19-0009
As part of the partnership with the ACC, Veradigm now operates the PINNACLE Registry and the Diabetes Collaborative Registry. Life science researchers have access to the largest combined cardiovascular database and one of the largest metabolic database, with over 20 million patients, for a variety of scientific studies.
To date, PINNACLE Registry and Diabetes Collaborative Registry research has been used to highlight real-world impacts of new clinical guidelines and identify where gaps in evidence-based care exist.